Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP is scheduled to post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.02 per share for the quarter.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, meeting analysts' consensus estimates of $0.01. The firm had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The firm's revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) earnings per share. On average, analysts expect Aurinia Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH traded down $0.15 during mid-day trading on Thursday, reaching $7.21. The stock had a trading volume of 824,998 shares, compared to its average volume of 1,602,491. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -17.12 and a beta of 1.44. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.05. The business has a 50 day simple moving average of $7.00 and a 200 day simple moving average of $5.99.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company's stock, valued at approximately $2,423,154.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AUPH shares. Cantor Fitzgerald restated an "overweight" rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.